Shire to sell oncology business for $2.4bn

17-04-2018

Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.


Shire, Mergers & Acquisitions, biotechnology, Servier, oncology, cancer, Takeda, M&A

LSIPR